Navigation Links
China Clean Energy Resumes Biodiesel Production After Temporary Halt
Date:11/11/2008

FUQING CITY, China, Nov. 11 /Xinhua-PRNewswire-FirstCall/ -- China Clean Energy Inc. (OTC Bulletin Board: CCGY) ("China Clean Energy", the "Company") today announced that, as of November 10, 2008 it has resumed biodiesel production.

China Clean Energy decided to resume biodiesel production at its existing plant in light of a recent drop in raw material prices, thus allowing the Company to enjoy sufficient margins to make this business segment profitable again. Currently the selling price of biodiesel is in the range of RMB5,500- RMB6,000, as compared to approximately RMB4,800 in second quarter of 2008. Feedstock prices, including yellow grease, cotton seed waste and rape seed waste are currently around RMB2,500-RMB2,700 per ton. At current prices for biodiesel and feedstock, the Company expects to achieve a 23% gross margin on its biodiesel product.

China Clean Energy expects to source its feedstock domestically this quarter and expects to produce up to 800 tons of biodiesel per month from its existing plant (which plant has annual capacity of 10,000 tons).

"We are very excited that we have moved back into producing biodiesel. We are also hopeful that the continued growth in the demand for fuel in China will allow us to operate our biodiesel plant at close to full capacity and help us improve our revenue and profit growth in the quarters ahead," said Mr. Tai-Ming Ou, CEO and Chairman of China Clean Energy Inc.

About China Clean Energy:

China Clean Energy, through its wholly-owned subsidiaries, Fujian Zhongde Technology Co., Ltd. and Fujian Zhongde Energy Co., Ltd, is engaged in the development, manufacturing, and distribution of biodiesel as well as specialty chemical products made from renewable resources.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the Company's ability to raise additional capital to finance the Company's activities; the effectiveness, profitability, and the marketability of its products; the availability of raw material feedstock at reasonable prices; the future trading of the common stock of the Company; the ability of the Company to expand its production capacity; the period of time for which its current liquidity will enable the Company to fund its operations; the Company's ability to protect its proprietary information; general economic and business conditions; the volatility of the Company's operating results and financial condition; the Company's ability to attract or retain qualified senior management personnel and research and development staff; and other risks detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company and the industry. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward looking statements are reasonable, they cannot assure you that their expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results.

For more information, please contact:

China Clean Energy Inc.

Shannon Yan, CFO

Email: shannon.yan@chinacleanenergyinc.com

CCG Elite Investor Relations Inc.

Crocker Coulson, President

Phone: +1-646-213-1915 (New York)

Ed Job, CFA

Phone: +1-646-213-1914

Email: ed.job@ccgir.com


'/>"/>
SOURCE China Clean Energy Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Medicine Announces Conference Call to Discuss Third Quarter 2008 Results
2. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
3. China Sky One Medical, Inc. Announces Conference Call to Discuss Third Quarter 2008 Results
4. China Pharma Holdings, Inc. to Present at Two Upcoming U.S. Investor Conferences
5. China Yingxia to Present at Roth China Comes to Vegas Conference
6. PAREXEL Expert to Address Key Aspects of Conducting Clinical Trials in China at 7th Annual Partnerships in Clinical Trials Congress
7. Sinovac Named to Deloitte Technology Fast 50 China
8. Sundia MediTech Ranked #16 in Deloitte Technology Fast 50 China
9. China Medical Technologies Announces Reporting Dates for the September Quarter Results and Addresses Investor Inquiries
10. China Yingxia to Present at Rodman & Renshaw Annual Global Investment Conference
11. China Pharma Holdings, Inc. Appoints The Ruth Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):